AlphAIAlphAI — Financial news for AI agents
stocktitan.netOCT 91 min read$CLBT

Cellebrite: Pertento reports 5.2% passive stake

Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques each reported a 5.2% passive stake in Cellebrite DI Ltd. (CLBT), owning 13,164,696 shares with shared voting and dispositive power. The shares are directly owned by advisory clients, with no beneficial ownership claimed beyond pecuniary interest.

Original reporting
stocktitan.net
Published Oct 9, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 10, 2026, 1:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CLBT
Neutral
medium confidence
Mentioned
$CLBT
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The disclosure adds transparency but is unlikely to move the stock significantly.

02

Market read

Low relevance; routine ownership filing with modest stake.

03

Timing

on filing day

Relevance 4/10Novelty 4/10Timing: on filing day

Background

Cellebrite (CLBT) filed a Schedule 13G showing Pertento Partners and advisors own 5.2% of its shares on a passive basis.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

Cellebrite disclosed a 5.2% passive stake via a Schedule 13G filing, indicating new beneficial ownership.

Expected impact

likely minimal impact as the passive stake is disclosed

Evidence & confidence

A 5.2% passive stake is not large enough to shift control or trigger significant trading activity.

Market effects

Sector

none

Regional

US

Global

low

Key entities

  • company
    Cellebrite DI Ltd.

    US-listed digital forensics company

  • investment advisor
    Pertento Partners LLP

    Advisory client holding passive stake

Read at source← All news

Related articles

AUG 20
$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

yahoo.com3 min
AUG 16
$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

simplywall.st6 min
AUG 15
$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

yahoo.com6 min
AUG 14
$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.

simplywall.st3 min